Mostrar el registro sencillo

dc.contributor.authorUruzubieta, Paula
dc.contributor.authorMedina, Juan Manuel
dc.contributor.authorFernandez López, Raúl
dc.contributor.authorCrespo, Javier
dc.contributor.authorCruz Calahorra, Fernando de la 
dc.contributor.otherUniversidad de Cantabriaes_ES
dc.date.accessioned2021-04-15T11:54:53Z
dc.date.available2021-04-15T11:54:53Z
dc.date.issued2020
dc.identifier.issn2077-0383
dc.identifier.otherBFU2017-86378-Pes_ES
dc.identifier.urihttp://hdl.handle.net/10902/21245
dc.description.abstractNon-alcoholic fatty liver disease (NAFLD) is a multifactorial disease in which environmental and genetic factors are involved. Although the molecular mechanisms involved in NAFLD onset and progression are not completely understood, the gut microbiome (GM) is thought to play a key role in the process, influencing multiple physiological functions. GM alterations in diversity and composition directly impact disease states with an inflammatory course, such as non-alcoholic steatohepatitis (NASH). However, how the GM influences liver disease susceptibility is largely unknown. Similarly, the impact of strategies targeting the GM for the treatment of NASH remains to be evaluated. This review provides a broad insight into the role of gut microbiota in NASH pathogenesis, as a diagnostic tool, and as a therapeutic target in this liver disease. We highlight the idea that the balance in metabolic fermentations can be key in maintaining liver homeostasis. We propose that an overabundance of alcohol-fermentation pathways in the GM may outcompete healthier, acid-producing members of the microbiota. In this way, GM ecology may precipitate a self-sustaining vicious cycle, boosting liver disease progression.es_ES
dc.description.sponsorshipFunding: This work was supported by grants from the Spanish Ministry of Science and Technology (grant BFU2017-86378-P) (to FdlC), Fondo Investigaciones Sanitarias (PI18/01304) (to JC), Gilead Fellowship programme 2018 (to JC).es_ES
dc.format.extent17es_ES
dc.publisherMDPIes_ES
dc.rightsAttribution-NoDerivatives 4.0 Internationales_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nd/4.0/*
dc.sourceJ Clin Med 2020 May 7;9(5):1369es_ES
dc.subject.otherNAFLDes_ES
dc.subject.otherGut microbiomees_ES
dc.subject.otherMicrobial metabolic pathwayes_ES
dc.subject.otherMicrobiome-based signatures_ES
dc.subject.otherFecal microbiota transplantationes_ES
dc.titleA Role for Gut Microbiome Fermentative Pathways in Fatty Liver Disease Progressiones_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherVersionhttps://www.mdpi.com/709510es_ES
dc.rights.accessRightsopenAccesses_ES
dc.identifier.DOI10.3390/jcm9051369
dc.type.versionpublishedVersiones_ES


Ficheros en el ítem

Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo

Attribution-NoDerivatives 4.0 InternationalExcepto si se señala otra cosa, la licencia del ítem se describe como Attribution-NoDerivatives 4.0 International